☆ 4.6 Article

The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Kathrin Heinrich et al.

Summary: This study retrospectively analyzed the first 1000 cases of the University of Munich Molecular Tumor Board (MTB) precision oncology program. The results showed that patients with breast and biliary tract cancers were more likely to have actionable genetic variants. However, only 17% of patients implemented the treatment recommendations from the tumor board, highlighting the importance of meticulous follow-up and broad access to innovative therapies for these patients.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board

Klara Dorman et al.

Summary: This study reviewed the discussions of patients with pancreatic cancer in the Molecular Tumor Board at CCCMunich(LMU) to gain a better understanding of the challenges and opportunities of precision oncology in this hard-to-treat cancer. The results showed that very few patients ultimately received the recommended therapies, highlighting the need for more and better targeted treatment options in pancreatic cancer.

TARGETED ONCOLOGY (2023)

添加到收藏夹

Editorial Material Oncology

A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group

Michele Bartoletti et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

添加到收藏夹

Article Oncology

Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience

Bryan H. Louie et al.

Summary: Personalized combination therapy based on molecular characteristics can be more effective for advanced colorectal cancer. The implementation of a Molecular Tumor Board (MTB) led to improved progression-free survival in patients by matching drugs to individual tumor alterations.

MOLECULAR ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Delivering precision oncology to patients with cancer

Joaquin Mateo et al.

Summary: Precision medicine is reshaping cancer care, but accessibility to all patients remains a challenge. This Perspective highlights the importance of addressing the challenges in implementing precision oncology, including equal access to genomics tests, robust evidence for new drugs and technologies, interpretation of genomics data by physicians, and empowering patients in shared decision-making.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah et al.

Summary: Pralsetinib is a potent and selective inhibitor of RET receptor tyrosine kinase, showing promising efficacy in patients with diverse RET fusion-positive solid tumors. It demonstrates rapid, robust, and durable anti-tumor activity, regardless of tumor type or RET fusion partner.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

Takashi Kohno et al.

Summary: Since June 2019, Japan has implemented cancer genomic medicine under the national health insurance system. With the establishment of a network of CGM hospitals and a national datacenter, clinical and genomic data from comprehensive genomic profiling tests are securely transferred and aggregated. The data are used to generate reports containing clinical annotation and information on matched clinical trials, which are now open for sharing with CGM hospitals, academic institutions, and industries.

CANCER DISCOVERY (2022)

添加到收藏夹

Review Genetics & Heredity

Clinical trial design in the era of precision medicine

Elena Fountzilas et al.

Summary: Recent breakthroughs in biotechnology have allowed for the identification of unique molecular features that drive malignancies. Precision medicine has used next-generation sequencing and matched targeted therapy/immunotherapy to transform the outlook for fatal cancers. Multiple trial designs and personalized combination treatment strategies have been implemented to accelerate drug evaluation and individualized treatment.

GENOME MEDICINE (2022)

添加到收藏夹

Article Oncology

MatchMiner: an open-source platform for cancer precision medicine

Harry Klein et al.

Summary: This article introduces an open-source platform called MatchMiner, which computationally matches genomically profiled cancer patients to precision medicine trials, accelerating the trial enrollment process. It provides data to demonstrate the impact of MatchMiner on trial consents.

NPJ PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero et al.

Summary: This article presents the implementation of the Molecular Tumor Board Portal, a system that integrates and interprets genomics and clinical data to support clinical decision-making in precision oncology. The system automates the interpretation and reporting of sequencing results, reducing errors and promoting consistent decision-making and data capture. It also facilitates collaborative discussion through information-rich patient reports and interactive content.

NATURE CANCER (2022)

添加到收藏夹

Article Genetics & Heredity

Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank

Joseph D. Szustakowski et al.

Summary: The UK Biobank Exome Sequencing Consortium is a successful collaborative project between UK Biobank and biopharmaceutical companies, providing valuable rare coding variation resources for drug discovery. The project has strengthened academic and industry ties and promoted interaction and learning within the wider research community.

NATURE GENETICS (2021)

添加到收藏夹

Review Oncology

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

Kara L. Larson et al.

Summary: This systematic review evaluated the impact of Molecular Tumor Board (MTB) review on clinical outcomes in cancer patients. 14 studies with 3,328 patients were included, showing improved clinical outcomes with MTB-recommended therapy. More prospective trials and standardization of approach and outcomes are needed for future research.

JCO PRECISION ONCOLOGY (2021)

添加到收藏夹

Review Genetics & Heredity

Molecular profiling for precision cancer therapies

Eoghan R. Malone et al.

GENOME MEDICINE (2020)

添加到收藏夹

Article Oncology

Implementation of a molecular tumor board at a regional level to improve access to targeted therapy

Heloise Bourien et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Shumei Kato et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Oncology

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F. Mosele et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

J. Mateo et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience

Todd C. Knepper et al.

ONCOLOGIST (2017)

添加到收藏夹

Article Oncology

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board

W. Brian Dalton et al.

JCO PRECISION ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center

Laura J. Tafe et al.

ONCOLOGIST (2015)

添加到收藏夹

Article Oncology

Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience

Maria Schwaederle et al.

ONCOLOGIST (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.